Assess whether RWE can replace or only supplement an RCT (31381d)

Situation

The desk packet is disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal. 505(b)(2) development lead in a mid-size sponsor after a complete response letter has to name RWE can replace or Only supplement an RCT for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• A DSMB note on an imbalance that is not yet a signal is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given disproportionate reporting signal workbook.
• A DSMB note on an imbalance that is not yet a signal is the event in disproportionate reporting signal workbook that forces RWE can replace for 505(b)(2) development lead under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after a DSMB note on an imbalance that is not yet a signal, not a Clinical and Evidence Strategy program failure.
• Disproportionate reporting signal workbook cannot decide RWE can replace or yet after a DSMB note on an imbalance that is not yet a signal; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move RWE can replace or for 505(b)(2) development lead.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.